Broncho-Vaxom

Phase 3Small molecule

OOM Pharma SA

Broncho-Vaxom is one of 115 small molecule programs targeting Respiratory tract infection. It is currently in Phase 3.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

WheezingActive, not recruiting

Atopic DermatitisActive, not recruiting

COVID-19Active, not recruiting

AsthmaActive, not recruiting

Idiopathic Nephrotic SyndromeActive, not recruiting

Respiratory Tract InfectionPhase 3

Active, not recruiting

WheezingPhase 2

Active, not recruiting

Atopic DermatitisPhase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Idiopathic Nephrotic SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Broncho-Vaxom

OOM Pharma SA

Phase 3

1 2

Spikevax

Moderna

Preclinical

21 3

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 4

Nitrostat

VViatris Specialty LLC

Preclinical

1 5

Aprotinin

Bayer

Preclinical

1 6

Antithrombin-III

Octapharma

Preclinical

1 7

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

1 8

DAS181

AAnsun Biopharma, Inc.

Preclinical

4 9

CAP-1002

CCapricor Inc.

Preclinical

2 10

Mrna-1273.211

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Respiratory Tract Infection

NCT05063149

Clinical

Trials by Indication[1]

Asthma1 trial

PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT04129931·395 enrolled

Idiopathic Nephrotic Syndrome1 trial

Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

Unknown status·FFang Deng·N/A·NCT05044169·83 enrolled

COVID-191 trial

Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85

Completed·TThe University of Queensland·Phase 3·NCT04496245·59 enrolled

Respiratory tract infection1 trial

Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates.

Recruiting·FFranciscus Gasthuis·Phase 3·NCT05063149·500 enrolled

Wheezing1 trial

Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

Completed·UUniversity of Arizona·Phase 2·NCT02148796·822 enrolled

2 more indications

Immunomodulation1 trial

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

Terminated·OOM Pharma SA·Phase 2·NCT05222516·63 enrolled

Atopic Dermatitis1 trial

Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis

Completed·VVifor Pharma·Phase 3·NCT03047954·179 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Broncho-Vaxom. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Broncho-Vaxom compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Broncho-Vaxom. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OM Pharma SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOM Pharma SA

Broncho-Vaxom

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Asthma1 trial

Idiopathic Nephrotic Syndrome1 trial

COVID-191 trial

Respiratory tract infection1 trial

Wheezing1 trial

Immunomodulation1 trial

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News